Sen. Ron Johnson: 5 Questions for FDA About Pfizer Vaccine Approval – Centre for Research on Globalization

In his letter, Johnson asks these five questions:

1. Why didn’t the FDA grant full licensure for the Pfizer-BioNTech vaccine that is in use and available in the U.S.?

2. How are the Comirnaty and Pfizer-BioNTech COVID-19 vaccines “legally distinct” and what are the “certain differences”?

3. There is no doubt that the FDA’s action will lead to more vaccine mandates and increased pressure on those currently choosing not to get vaccinated. Your letter to Pfizer suggests that “there is not sufficient approved vaccine available for distribution.” Is there sufficient supply in the U.S. of the Comirnaty vaccine to ensure that those being vaccinated under mandates will be receiving the FDA-approved version? Or is it more likely (or certain) that they will be vaccinated using the vaccine administered under the reissued EUA?

4. If there is insufficient supply of Comirnaty vaccines for those succumbing to the coercion of mandates, isn’t the FDA de facto endorsing vaccine mandates utilizing EUA vaccines?

5. Will individuals who receive either vaccine be afforded the same legal protections if they are injured by the vaccine? If not, why not?

This isn’t the first time Johnson has written the FDA about COVID vaccines. On Aug. 22, he sent a letter to Woodcock; Dr. Francis Collins, director of the National Institutes of Health (NIH); and Dr. Rochelle P. Walensky, director of Centers for Disease Control and Prevention, criticizing the FDA’s decision not to hold a formal advisory committee meeting to discuss Pfizer’s application for full approval of its vaccine.

In July, Johnson held a news conference with families injured by the vaccines, during which he said the medical community was “repeatedly ignoring” the vaccine-injured.

Sen. Ron Johnson: 5 Questions for FDA About Pfizer Vaccine Approval – Global ResearchGlobal Research – Centre for Research on Globalization